信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002294 信立泰

已收盘 07-17 15:00:00

{"stockData":{"symbol":"002294","market":"SZ","secType":"STK","nameCN":"信立泰","latestPrice":28.28,"timestamp":1721199792000,"preClose":27.98,"halted":0,"volume":3044824,"delay":0,"floatShares":1115000000,"shares":1115000000,"eps":0.5108,"marketStatus":"已收盘","marketStatusCode":5,"change":0.3,"latestTime":"07-17 15:00:00","open":27.97,"high":28.44,"low":27.8,"amount":85878500,"amplitude":0.0229,"askPrice":28.28,"askSize":2,"bidPrice":28.27,"bidSize":13,"shortable":0,"etf":0,"ttmEps":0.5108,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721266200000},"adr":0,"adjPreClose":27.98,"symbolType":"stock","openAndCloseTimeList":[[1721179800000,1721187000000],[1721192400000,1721199600000]],"highLimit":30.78,"lowLimit":25.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1114816535,"pbRate":3.79,"roa":"--","roe":"2.47%","epsLYR":0.52,"committee":0.457627,"marketValue":31527000000,"floatMarketCap":31520000000,"peRate":55.364134,"changeRate":0.0107,"turnoverRate":0.0027,"status":0},"requestUrl":"/m/hq/s/002294","defaultTab":"news","newsList":[{"id":"2449253466","title":"信立泰最新公告：苯甲酸福格列汀片（信立汀）获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449253466","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449253466?lang=zh_cn&edition=full","pubTime":"2024-07-05 16:24","pubTimestamp":1720167846,"startTime":"0","endTime":"0","summary":"信立泰公告，近日，公司收到国家药品监督管理局核准签发的苯甲酸福格列汀片（商品名：信立汀）药品注册证书。苯甲酸福格列汀片（信立汀）是一种二肽基肽酶4（DPP-4）抑制剂，用于改善成人2型糖尿病患者的血糖控制。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500030131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0196","BK0183","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2449230295","title":"信立泰(002294.SZ)：苯甲酸福格列汀片(信立汀)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2449230295","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449230295?lang=zh_cn&edition=full","pubTime":"2024-07-05 15:59","pubTimestamp":1720166386,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司收到国家药品监督管理局核准签发的苯甲酸福格列汀片(商品名：信立汀)药品注册证书。据悉，苯甲酸福格列汀片(信立汀)是一种二肽基肽酶4(DPP-4)抑制剂，用于改善成人2型糖尿病患者的血糖控制(包括单药治疗，以及单独使用盐酸二甲双胍不能有效控制血糖时的联合治疗)，为国产1类创新药(项目代码：SAL067)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1146080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0183","BK0239","BK0187","BK0028","002294","BK0188"],"gpt_icon":0},{"id":"2448933413","title":"信立泰（002294）6月28日主力资金净卖出410.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448933413","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448933413?lang=zh_cn&edition=full","pubTime":"2024-07-01 09:23","pubTimestamp":1719797032,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月28日收盘，信立泰报收于26.63元，下跌1.92%，换手率0.3%，成交量3.36万手，成交额9030.83万元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1063.08万元，融资偿还746.93万元，融资净买入316.15万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100003762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0196","BK0028","BK0239","BK0188","002294","BK0187"],"gpt_icon":0},{"id":"2446099899","title":"信立泰最新公告：SAL056上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2446099899","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446099899?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:35","pubTimestamp":1719304531,"startTime":"0","endTime":"0","summary":"信立泰公告，子公司信立泰(苏州)药业有限公司的生物药“注射用特立帕肽”(SAL056)申报上市申请获得国家药品监督管理局受理。SAL056是长效骨形成促进剂，每周一次皮下注射，拟用于治疗有骨折高发风险的绝经后妇女骨质疏松症。目前国内尚无同规格及用法用量的产品。若获批上市，将大幅提高患者用药便利性。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062500030973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0196","002294","BK0183","BK0028","BK0188","BK0239"],"gpt_icon":0},{"id":"2446962198","title":"信立泰(002294.SZ)：“注射用特立帕肽”上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2446962198","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446962198?lang=zh_cn&edition=full","pubTime":"2024-06-25 16:10","pubTimestamp":1719303046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司子公司信立泰(苏州)药业有限公司在研的生物药“注射用特立帕肽”(项目代码：SAL056)申报上市申请获得国家药品监督管理局受理，拟申请适应症为：治疗有骨折高发风险的绝经后妇女骨质疏松症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","002294","BK0239","BK0028","BK0187","BK0188","BK0196"],"gpt_icon":0},{"id":"2444967784","title":"信立泰（002294）6月18日主力资金净买入585.67万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444967784","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444967784?lang=zh_cn&edition=full","pubTime":"2024-06-19 09:04","pubTimestamp":1718759092,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月18日收盘，信立泰报收于27.95元，下跌1.55%，换手率0.29%，成交量3.18万手，成交额8933.3万元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1129.08万元，融资偿还290.82万元，融资净买入838.25万元，连续3日净买入累计961.1万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061900014403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","BK0183","BK0239","BK0188","002294","BK0196"],"gpt_icon":0},{"id":"2443908849","title":"信立泰公布国际专利申请：“一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2443908849","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443908849?lang=zh_cn&edition=full","pubTime":"2024-06-16 04:33","pubTimestamp":1718483609,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示信立泰公布了一项国际专利申请，专利名为“一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途”，专利申请号为PCT/CN2023/136923，国际公布日为2024年6月13日。专利详情如下：图片来源：世界知识产权组织今年以来信立泰已公布的国际专利申请5个，较去年同期增加了25%。结合公司2023年年报财务数据，2023年公司在研发方面投入了4.09亿元，同比减23.34%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061600000314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","159938","BK0239","002294","BK0187","BK1161","09939","BK0196","BK1574","BK0188","BK0028","BK0183"],"gpt_icon":0},{"id":"2443661507","title":"信立泰（002294）6月13日主力资金净卖出930.63万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2443661507","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443661507?lang=zh_cn&edition=full","pubTime":"2024-06-14 09:12","pubTimestamp":1718327579,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月13日收盘，信立泰报收于28.94元，上涨3.88%，换手率0.71%，成交量7.92万手，成交额2.28亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入440.04万元，融资偿还2341.26万元，融资净偿还1901.22万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061400012939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0028","BK0188","BK0239","002294","BK0196"],"gpt_icon":0},{"id":"2442395257","title":"信立泰最新公告：2023年年度权益分派10派5元 股权登记日6月18日","url":"https://stock-news.laohu8.com/highlight/detail?id=2442395257","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442395257?lang=zh_cn&edition=full","pubTime":"2024-06-11 20:49","pubTimestamp":1718110195,"startTime":"0","endTime":"0","summary":"信立泰公布2023年年度权益分派实施公告，公司2023年年度权益分派方案为：向全体股东每10股派5元人民币现金(含税)。本次权益分派股权登记日为：2024年6月18日，除权除息日为：2024年6月19日。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100029405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","002294","BK0187","BK0028","BK0183","BK0239","BK0188"],"gpt_icon":0},{"id":"2442366629","title":"信立泰(002294.SZ)2023年年度权益分派：每10股派5元 6月18日股权登记","url":"https://stock-news.laohu8.com/highlight/detail?id=2442366629","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442366629?lang=zh_cn&edition=full","pubTime":"2024-06-11 18:38","pubTimestamp":1718102304,"startTime":"0","endTime":"0","summary":"信立泰(002294.SZ)发布公告，公司2023年年度权益分派方案为：以公司现有...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/8.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1133639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0188","BK0187","002294","BK0196","BK0028","BK0183","BK0239"],"gpt_icon":0},{"id":"2442044478","title":"信立泰（002294）6月7日主力资金净卖出697.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2442044478","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2442044478?lang=zh_cn&edition=full","pubTime":"2024-06-11 09:22","pubTimestamp":1718068977,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月7日收盘，信立泰报收于27.26元，下跌1.77%，换手率0.31%，成交量3.44万手，成交额9440.26万元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入598.47万元，融资偿还1086.93万元，融资净偿还488.46万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061100002304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0187","002294","BK0196","BK0028","BK0183","BK0239"],"gpt_icon":0},{"id":"2441295847","title":"信立泰（002294）6月4日主力资金净买入209.82万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2441295847","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441295847?lang=zh_cn&edition=full","pubTime":"2024-06-05 09:17","pubTimestamp":1717550236,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年6月4日收盘，信立泰报收于27.75元，上涨2.55%，换手率0.4%，成交量4.43万手，成交额1.22亿元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入872.5万元，融资偿还1333.69万元，融资净偿还461.19万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060500015529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","002294","BK0183","BK0196","BK0239","BK0188"],"gpt_icon":0},{"id":"2437924954","title":"信立泰(002294.SZ)：阿利沙坦酯氨氯地平片(复立坦®)获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2437924954","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437924954?lang=zh_cn&edition=full","pubTime":"2024-05-21 18:03","pubTimestamp":1716285805,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰 发布公告，近日，公司收到国家药品监督管理局核准签发的阿利沙坦酯氨氯地平片(复立坦)药品注册证书。据悉，阿利沙坦酯氨氯地平片(复立坦)用于治疗原发性高血压，适用于单用阿利沙坦酯或单用氨氯地平治疗血压控制效果不佳的成人患者，为国产原研ARB/CCB类复方制剂。其组分经典，可靠性高，降压疗效得到充分验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123945.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0196","BK0188","002294","BK0187","BK0183","BK0028"],"gpt_icon":0},{"id":"2436913093","title":"信立泰：截至2月8日，公司股东人数27,215","url":"https://stock-news.laohu8.com/highlight/detail?id=2436913093","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436913093?lang=zh_cn&edition=full","pubTime":"2024-05-17 20:04","pubTimestamp":1715947485,"startTime":"0","endTime":"0","summary":"投资者：请问截止2月8日收盘公司股东人数是多少？截至3月8日，公司股东人数29,469。公司大股东未减持股份，其持有公司63527.938万股，占公司总股本约56.99%。经问询股东，近期中信里昂资产管理有限公司－客户资金发生大宗交易合计股数1922.55万股，目前持有股份数占公司总股本约2.97%。恩那罗23年6月获批上市，23年12月通过谈判首次纳入医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700043030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0239","BK0028","BK0188","BK0187","BK0196","BK0183"],"gpt_icon":0},{"id":"2436375789","title":"信立泰（002294）5月16日主力资金净卖出172.88万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436375789","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436375789?lang=zh_cn&edition=full","pubTime":"2024-05-17 09:22","pubTimestamp":1715908949,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月16日收盘，信立泰报收于29.56元，下跌1.6%，换手率0.28%，成交量3.1万手，成交额9239.97万元。近5日资金流向一览见下表：信立泰融资融券信息显示，融资方面，当日融资买入1009.35万元，融资偿还783.25万元，融资净买入226.1万元。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700015548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0187","BK0196","BK0183","BK0028","BK0239","BK0188"],"gpt_icon":0},{"id":"2435341613","title":"信立泰(002294.SZ)股东润复拟向基金会无偿捐赠200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2435341613","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435341613?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:58","pubTimestamp":1715590732,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信立泰(002294.SZ)公告，公司近日收到股东深圳市润复投资发展有限公司(下称“润复”)《关于无偿捐赠部分股份的告知函》，其计划将所持有的无限售条件流通股200万股(占公司总股本比例0.18%)无偿捐赠给深圳市叶澄海慈善基金会(下称“基金会”)。基金会出售股份所得款项，将全部用于捐资助学等公益事业。其中，将定向捐赠不少于5000万元人民币给深圳大学，剩余款项将用于基金会开展慈善公益活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1120493.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0183","BK0239","002294","BK0187","BK0028","BK0188"],"gpt_icon":0},{"id":"2435499543","title":"5月13日信立泰现4.96亿元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2435499543","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435499543?lang=zh_cn&edition=full","pubTime":"2024-05-13 16:40","pubTimestamp":1715589649,"startTime":"0","endTime":"0","summary":"证券之星消息，5月13日信立泰发生大宗交易，交易数据如下：大宗交易成交价格30.72元，成交1613.33万股，成交金额49561.5万元，买方营业部为机构专用，卖方营业部为机构专用。近三个月该股共发生2笔大宗交易，合计成交35.36万手，折价成交1笔。截至2024年5月13日收盘，信立泰报收于30.72元，下跌1.57%，换手率0.31%，成交量3.42万手，成交额1.05亿元。该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为38.57。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051300015974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0188","002294","BK0187","BK0196","BK0183"],"gpt_icon":0},{"id":"2433296337","title":"天风证券：给予信立泰买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433296337","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433296337?lang=zh_cn&edition=full","pubTime":"2024-05-07 10:56","pubTimestamp":1715050595,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松,曹文清近期对信立泰进行研究并发布了研究报告《2023年业绩基本稳定，2024年Q1收入增长回正》，本报告对信立泰给出买入评级，当前股价为31.42元。该团队在推广信立坦产品方面已展现出明显成效，预计未来将继续利用其优势，推动公司业务的进一步增长。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有9家机构给出评级，买入评级7家，增持评级2家；过去90天内机构目标均价为38.57。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050700017456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601162","002294"],"gpt_icon":0},{"id":"2433445367","title":"信立泰（002294）股东信立泰药业有限公司质押1600万股，占总股本1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433445367","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433445367?lang=zh_cn&edition=full","pubTime":"2024-05-06 03:30","pubTimestamp":1714937442,"startTime":"0","endTime":"0","summary":"证券之星消息，信立泰5月6日公开信息显示，股东信立泰药业有限公司向澳门国际银行股份有限公司合计质押1600.0万股，占总股本1.44%。质押详情见下表：截止本公告日，股东信立泰药业有限公司已累计质押股份2.0亿股，占其持股总数的31.53%。信立泰主营业务：药品、医疗器械产品的研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050600000074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0196","BK0187","BK0183","BK0239","002294"],"gpt_icon":0},{"id":"2429125657","title":"信立泰（002294）2024年一季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2429125657","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429125657?lang=zh_cn&edition=full","pubTime":"2024-04-24 06:15","pubTimestamp":1713910533,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期信立泰发布2024年一季报。根据财报显示，本报告期中信立泰增收不增利。截至本报告期末，公司营业总收入10.91亿元，同比上升22.92%，归母净利润2.0亿元，同比下降5.06%。重仓信立泰的前十大基金见下表：持有信立泰最多的基金为广发医疗保健股票A，目前规模为58.21亿元，最新净值1.6097，较上一交易日上涨1.85%，近一年下跌24.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400012002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002294","BK0239","BK0028","BK0188","BK0187","BK0196","BK0183"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2009-09-10","address":"广东省深圳市福田区福保街道福保社区红柳道2号289数字半岛4层A区","stockEarnings":[{"period":"1week","weight":0.047},{"period":"1month","weight":0.0142},{"period":"3month","weight":-0.0005},{"period":"6month","weight":-0.0054},{"period":"1year","weight":-0.099},{"period":"ytd","weight":-0.1183}],"companyName":"深圳信立泰药业股份有限公司","boardCode":"AI0027","perCapita":"41336股","boardName":"医药制造业","registeredCapital":"111481万元","compareEarnings":[{"period":"1week","weight":0.008},{"period":"1month","weight":-0.0176},{"period":"3month","weight":-0.0362},{"period":"6month","weight":0.0461},{"period":"1year","weight":-0.0735},{"period":"ytd","weight":-0.0041}],"survey":"　　深圳信立泰药业股份有限公司主营业务是药品、医疗器械产品的研发、生产、销售。主要产品心血管类药物及医疗器械、头孢类抗生素及原料、骨科药物等。","serverTime":1721255561601,"listedPrice":41.98,"stockholders":"26963人(较上一季度减少2.58%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"信立泰,002294,信立泰股票,信立泰股票老虎,信立泰股票老虎国际,信立泰行情,信立泰股票行情,信立泰股价,信立泰股市,信立泰股票价格,信立泰股票交易,信立泰股票购买,信立泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"信立泰(002294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供信立泰(002294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}